High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting-Reference-Cited by-同舟云学术

High-levelERBB2gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting

Published:2014-01-28 Issue:1 Volume:135 Page:224-231
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Fuchs Eva-Maria¹²,Köstler Wolfgang J.²³,Horvat Reinhard⁴,Hudelist Gernot¹,Kubista Ernst¹,Attems Johannes⁵⁶,Zielinski Christoph C.²³,Singer Christian F.¹³

Affiliation:

1. Department of Obstetrics and Gynecology; Medical University of Vienna; Vienna Austria

2. Department of Medicine I; Division of Oncology; Medical University of Vienna; Vienna Austria

3. Comprehensive Cancer Center; Medical University of Vienna; Vienna Austria

4. Department of Clinical Pathology; Medical University of Vienna; Vienna Austria

5. Pathologic-Bacteriologic; Institute, SMZ Otto Wagner Hospital; Vienna Austria

6. Institute for Ageing and Health; Newcastle University; Wolfson Research Centre, Campus for Ageing and Vitality Newcastle upon Tyne United Kingdom

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference26 articles.

1. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells;Nahta;Cancer Res,2005

2. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors;Hudelist;Breast Cancer Res Treat,2003

3. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions;Alroy;FEBS Lett,1997

4. Her-2/neu-triggered intracellular tyrosine kinase activation: in vivo relevance of ligand-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment;Hudelist;Br J Cancer,2003

5. Serum levels of C-erbB-2 (HER-2/neu) in patients with malignant and non-malignant diseases;Molina;Tumour Biol,1997

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inflammatory breast cancer: An overview about the histo-pathological aspect and diagnosis;International Review of Cell and Molecular Biology;2024

2. HER2 copy number determination in breast cancer using the highly sensitive droplet digital PCR method;Virchows Archiv;2023-11-23

3. HER2 Amplification Level Predicts Pathological Complete Response in the Neoadjuvant Setting of HER2-Overexpressing Breast Cancer: A Meta-Analysis and Systematic Review;International Journal of Molecular Sciences;2023-02-10

4. Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer;Cancers;2022-06-04

5. HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer;The Breast;2022-04